Frontiers in Neurology · 2018 · 175 citations · 29 references
Life SciencesNeurologyNeurodegenerationNeuroimmunologySubstance Use DisordersDemyelinating DiseasesDemyelinating DisordersMultiple SclerosisTobacco UseMultiple Sclerosis AssociationsSmoking EpidemiologySymptom Onset AnalysisSymptom Onset TimingTobacco Smoking
Background: Age at symptom onset (ASO) is a prognostic factor that could affect the accrual of disability in multiple sclerosis (MS) patients. Some factors are known to influence the risk of multiple sclerosis (MS), but their influence on the ASO is less well-investigated. Objective: Examine the associations between known or emerging MS risk factors and ASO. Methods: This was a multicentre study, incident cases (n=279) with first clinical diagnosis of demyelinating event aged 18–59 years recruited at four Australian centres (latitudes 27°S to 43°S), from 1 November 2003 to 31 December 2006. Environmental/behavioural variables and initial symptoms were recorded at baseline interview. Linear regression was used to assess the association between risk factors and ASO. Results: Five factors were significantly associated with ASO: a history of tobacco smoking was associated with 3.05-years later ASO (p=0.002); a history of marijuana use was associated with 6.03-years earlier ASO (p<0.001); progressive-onset cases had 5.61-years later ASO (p=0.001); an initial presentation of bowel & bladder and cerebral dysfunctional were associated with 3.39 (p=0.017) and 4.37-years (p=0.006) later ASO, respectively. Other factors, including sex, offspring number, latitude of study site, history of infectious mononucleosis, HLA-DR15 & HLA-A2 genotype, 25(OH)D levels, and ultraviolet radiation exposure were not associated with ASO. Including all five significant variables into one model explained 12% of the total variance in ASO. Conclusion: We found a novel association between a history of tobacco smoking and later onset, whereas marijuana use was associated with earlier onset. Behavioural factors seem important drivers of MS onset timing although much of the variance remains unexplained.
29
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
Stephen Sawcer, Maria Ban, Anu Kemppinen et al. · Nature · 2011 · 2.7K citations · Full text
Life Sciences, Immunology, Neurology +17
Serum 25-Hydroxyvitamin D Levels and Risk of Multiple Sclerosis
Kassandra L. Munger, Lynn I. Levin, Bruce W. Hollis et al. · JAMA · 2006 · 1.9K citations
Life Sciences, Nutritional Sciences, Micronutrient Deficiency +13
Natural history of multiple sclerosis: a unifying concept
Christian Confavreux, Sandra Vukusic · Brain · 2006 · 889 citations · Full text
Evidence for a two-stage disability progression in multiple sclerosis
Emmanuelle Leray, Jacqueline Yaouanq, Emmanuelle Le Page et al. · Brain · 2010 · 587 citations · Full text
Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study
Ingrid van der Mei, Terence Dwyer, Leigh Blizzard et al. · BMJ · 2003 · 554 citations · Full text